CLINICAL TRIALS PROFILE FOR DEXLANSOPRAZOLE

All Clinical Trials for dexlansoprazole

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00251693 ↗	Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis	Completed	Takeda	Phase 3	2005-12-01	The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
NCT00251719 ↗	Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis	Completed	Takeda	Phase 3	2005-12-01	This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
NCT00251745 ↗	Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn	Completed	Takeda	Phase 3	2005-12-01	The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00251758 ↗	Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn	Completed	Takeda	Phase 3	2005-12-01	The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00255151 ↗	Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis	Completed	Takeda	Phase 3	2006-01-01	The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
NCT00255164 ↗	Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis	Completed	Takeda	Phase 3	2006-01-01	The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).

Clinical Trial Conditions for dexlansoprazole

Condition Name

Condition Name for dexlansoprazole
Intervention	Trials
Gastroesophageal Reflux Disease	13
Esophagitis, Peptic	5
Esophagitis, Reflux	5
Gastroesophageal Reflux	5

Condition MeSH

Condition MeSH for dexlansoprazole
Intervention	Trials
Gastroesophageal Reflux	26
Esophagitis, Peptic	17
Esophagitis	12
Heartburn	6

Clinical Trial Locations for dexlansoprazole

Trials by Country

Trials by Country for dexlansoprazole
Location	Trials
United States	461
China	33
Mexico	18
Canada	12
India	9

Trials by US State

Trials by US State for dexlansoprazole
Location	Trials
California	19
Arizona	18
Illinois	17
Texas	17
Ohio	17

Clinical Trial Progress for dexlansoprazole

Clinical Trial Phase

Clinical Trial Phase for dexlansoprazole
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	13
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for dexlansoprazole
Clinical Trial Phase	Trials
Completed	34
Unknown status	5
Withdrawn	5

Clinical Trial Sponsors for dexlansoprazole

Sponsor Name

Sponsor Name for dexlansoprazole
Sponsor	Trials
Takeda	31
Mayo Clinic	2
Ramathibodi Hospital	1

Sponsor Type

Sponsor Type for dexlansoprazole
Sponsor	Trials
Industry	35
Other	29